Маркетинговий аналіз антибактерійних препаратів групи азитроміцину для використання у педіатрії Мета: оцінка стану вітчизняного фармацевтичного ринку препаратів азитроміцину, які використовують для лікування інфекційних хвороб у дітей, зокрема кашлюка. Матеріали та методи: маркетинговий аналіз лікарських препаратів (ЛП) азитроміцину, проведений методом щомісячного моніторингу асортименту, середніх оптово-відпускних цін, коефіцієнтів соціально-економічної доступності (ліквідності ціни (C liq), адекватності платоспроможності населення (С a.s), доступності (D) за даними ресурсу «Програмний комплекс «Аптека» (http://pharmbase. com.ua/) за 2015 та 2017 роки. Результати дослідження. Виявлено, що станом на грудень 2017 р. серед препаратів азитроміцину домінували засоби іноземного виробництва (66 %): частка російських становила 23 %, ізраїльських-22 %, словенських-18 %. Серед вітчизняних виробників азитроміцинів найбільшу кількість представляли українсько-іспанське підприємство «Сперко Україна» та КМП (по 20 %). За лікарськими формами вони на 98 % належали до оральних засобів: таблетки (45 %), порошок для приготування суспензії (31 %), капсули (22 %). Ціновий аналіз препаратів азитроміцину у формі капсул по 250 мг № 6 та порошку для приготування суспензій виявив широкий діапазон оптово-відпускних цін. Серед упаковок капсульних засобів найдешевшими були вітчизняні генерики: Азитроміцин-КР (Червона зірка)-24,63 ± 0,22 грн й Азитроміцин-Астрафарм-24,94 ± 0,22 грн; а серед порошків для приготування суспензії-також український Азимед ® , 200 мг/5 мл, КМП (18,53 ± 0,7 грн за 1 DDD). Висновки. Оцінка соціально-економічної доступності препаратів азитроміцину за моніторингом коефіцієнтів ліквідності, адекватності платоспроможності населення, доступності дозволяє вважати їх фінансово доступними для середньостатистичної сім'ї в Україні з дитиною, хворою на кашлюк. Водночас аналіз форм випуску виявив недостатність педіатричних дозувань групи J01FA10. Ключові слова: азитроміцин; кашлюк; маркетинговий аналіз; фармацевтичний ринок; показники доступності. I. O. Fedyak, I. P. Bilyk The marketing analysis of antibacterial drugs of the azitrimicine group for use in pediatrics Aim. To assess the state of the Ukrainian pharmaceutical market for azithromycin drugs used to treat infection diseases in children, including pertussis. Materials and methods. The marketing analysis of azithromycin drugs was conducted by the method of monthly monitoring of the range, average wholesale prices, social and economic availability coefficients (cost liquidity (Cliq), adequacy of the population solvency (Ca.s), availability (A) according to the resource "Program complex "Apteka" (Pharmacy)" (http://pharmbase.com.ua/) for 2015 and 2017. Results. It was found that by December 2017 products of foreign manufacture were dominated (66 %) among azithromycin drugs: the share of Russian manufacturers was 23 %, Israeli-22 %, Slovenian-18 %. Among the domestic producers of azithromycin the Ukrainian-Spanish company Sperko Ukraine and KMP (by 20 %) represented the larg...

A comprehensive study for assessment the appointments rationality for children with meningococcal infectious (MI) in Ukraine in real clinical practice has been conducted. The doctor’s appointment sheets from 184 inpatients medical cards have been processed by the integral ABC / VEN / frequency analysis. In average, children were in the hospital (14±7) bed-days, they were granted 2908 appointments of 191 drugs by the INN. It has been established that medicine for MI etiotropic therapy took the third place in the appointments frequency. At the same time, the ABC / VEN-analysis results revealed a rational approach to pharmacotherapy.The total treatment cost was estimated at USD 25,173.59 (for one child – USD 136.81).Since currently in Ukraine inpatient children treatment is mainly provided by parents, further medical prescriptions improvement is needed in order to increase the efficiency and minimize the childrenMI therapy cost.

The aim: to conduct an analysis of the state of functioning of pharmaceutical supply systems for the population in European countries and Ukraine based on a set of socio-economic indicators. Materials and methods. General theoretical (historical, formal, graphic, hypothetical-deductive) and applied (organizational-economic, mathematical-statistical) research methods were used. The object of research was data that was freely available. Results. It was established that the highest volume of the pharmaceutical market volume per inhabitant is typical for Italy (410.18 euros) and the lowest for Ukraine (53.58 euros). It has been proven that with an increase in GDP indicators, which are calculated based on purchasing power parity (PPP) per capita, the range of variation of this indicator by groups decreases, and the number of countries with a negative value of the foreign trade balance also decreases. Within groups of countries, there is a different level of dependence on the import of pharmaceutical products. In Ukraine (the first group), imports exceeded the export data of pharmaceutical products by 8.6 times. For other countries in this group (Latvia, Bulgaria, and Slovakia), imports exceeded exports by 1.3, 1.4, and 4.0 times, respectively. The highest values of the volume of foreign trade in pharmaceutical products were characteristic of the countries of the third and second groups. The undisputed leader is Germany (134,541.0 million euros), in second place is Italy (59,533.0 million euros), and in third place is France (58,568.0 million euros). The highest values of health care costs as a percentage of GDP (%) are typical for the countries of the third group and the lowest for the countries of the first group. For all countries, this indicator had a characteristic tendency to increase over time. Growth rates varied both across groups and within groups across countries. According to the indicator of the amount of reimbursement of the cost of drug consumption per person, there was a significant fluctuation of the data by country within the groups. The most extensive range of fluctuations was observed in the third group (284.83 euros). The highest reimbursement amounts are typical for Germany (483.53 euros) and the lowest for Bulgaria (54.25 euros). In most countries, there is a high level (50.0 % and higher) of state participation in the payment of medicine, except for Poland (36.0 %), Lithuania (34.0 %) and Latvia (37.0 %). The lowest values of money consumers spend to pay for medicines (from 13.0 % to 44.0 %) are characteristic of the countries of the third group. Conclusions. The established peculiarities of the functioning of the pharmaceutical supply systems of European countries should not diminish the value of the state's aspirations to harmonize the processes that take place to promote medicinal products to consumers

The results of clinical and economic analysis of pharmacotherapy of children with pertussis (P), meningococcal disease (MD) and scarlet fever (SF) are given in the article. One hundred and ninety-seven medical histories of hospital patients have been analyzed for the period from 2011 to 2013. The correlation between the patients with P, MD, SF was 17:1,5:1. It has been found that the age group from 1 to 6 years old dominated among infants (43-67%), considerable gender differences were not revealed by pathologies; children with MD sharply dominated in the countryside (80%), as for those with SF, on the contrary, in the urban area (90%). The following medicines were prescribed more often; for treatment of P-the mixture with aminazine, no-spa, amp., tavegil, amp.; for MD therapy-Ringer's solution, isotonic solution, magnesium sulfate, amp.; for treatment of SF-ascorutin, tab., tavegil, amp., glucose, 5% solution. The most popular АТС-group for treatment of children with SF and МD was the group "Drugs affecting digestive system and metabolism", it took the second place in pharmacotherapy of infants with P. With the help of АВС-analysis medicines were classified by their contribution in overall costs, which were to average 683,62 UAH per one child with P, 1506,02 UAH per one child with MD, 582,12 UAH per one child with SF in the hospital procurement prices. It has been determined that financial expenses for therapy of ill children were sometimes economically ungrounded due to a great number of medicines with N-index (50-86.2%). Meanwhile, the assessment of reasonability of prescriptions for children with infectious diseases using "formal" VEN-analysis, cannot claim to be objective without review of clinical protocols of diagnostics and treatment in 2004, which presently require updating.

Introduction: The level of childhood bacterial diseases incidence does not have a downward trend. The aim: Conduction of a sociological analysis of medical cards for children with pertussis, meningococcal infection (MI), scarlet fever, and evaluation of consumed pharmacotherapy according to real clinical practice in Ukraine. Materials and methods: 1215 medical cards of inpatients; methods: sociological – document analysis, retrospective frequency. Results: Among the cards of children with pertussis: 50.2% – female, 49.8%– male; by age children up to 1 year (49.3%) were prevailed. In 79.6% incidence – medium-hard form pertussis, 42.2% with complications. Among patients with MI by sex there were: 50.5 % – boys and 49.5% – girls; by age – children aged 1-4 (40.2%); the structure of generalized forms of MI: 40.2% – meningococcemia, 11.4% – meningitis, 48.4% – combination. Scarlet fever was more frequently: boys (56.4%), children aged 5-9 (44.7%), urban residents (79.7%); it was 93.4% of a medium-hard form. Most of medicines were prescribed to children with MI – 15.8 trade names per 1 person, it was prescribed 191 INN, most often – Sodium chloride (90.0%), Ascorbic acid (68.5%), Ceftriaxone (65.8%); patients with pertussis – 11.2, 196 INN (Chlorpromazine (69.1%), Dexamethasone (53.2%), Butamirate (51.8%)); scarlet fever – 9.3 medicines, 114 INN (local action Comb drug for throat diseases treatment (94.4%), Ceftriaxone (48.7%), Metamizole sodium (38.1%)). Conclusions: Frequency analysis data of consumed pharmacotherapy in real pediatric practice in Ukraine shows the need for its further optimization in accordance with the principles of evidence-based medicine, the results of research on the socio-demographic characteristics of patients, forms and complications of course of the basic disease.